Compare SHIM & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SHIM | RCEL |
|---|---|---|
| Founded | 1990 | N/A |
| Country | United States | United States |
| Employees | N/A | 226 |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 149.2M | 126.8M |
| IPO Year | 2023 | N/A |
| Metric | SHIM | RCEL |
|---|---|---|
| Price | $3.70 | $5.02 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.88 |
| AVG Volume (30 Days) | 133.6K | ★ 358.7K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.95 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $492,844,000.00 | N/A |
| Revenue This Year | $13.99 | $17.17 |
| Revenue Next Year | $6.94 | $49.82 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.63 | N/A |
| 52 Week Low | $1.58 | $3.22 |
| 52 Week High | $6.76 | $7.12 |
| Indicator | SHIM | RCEL |
|---|---|---|
| Relative Strength Index (RSI) | 45.83 | 61.48 |
| Support Level | $3.43 | $3.47 |
| Resistance Level | $4.10 | $5.32 |
| Average True Range (ATR) | 0.34 | 0.45 |
| MACD | -0.01 | 0.05 |
| Stochastic Oscillator | 17.20 | 61.53 |
Shimmick Corp is engaged in delivering turnkey infrastructure solutions that strengthen critical markets across water, energy, climate resiliency, and sustainable transportation. It selectively focuses on the following types of infrastructure projects: Water Treatment, Water Resources, and Other Critical Infrastructure. In water treatment projects the company expands, rehabilitates, upgrades, builds and rebuilds water and wastewater treatment infrastructure. In Other Critical Infrastructure projects, It builds, retrofits, expands, rehabilitates, operates, and maintains critical infrastructure, including mass transit, bridges, and military infrastructure. The company has one operating and reportable segment: infrastructure solutions. All of its revenue is derived from the United States.
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.